PHARMACEUTICALS
Untitled Page
Spectrum Pharmaceuticals makes key move for bladder cancer drug
Irvine-based firm inks deal to market apaziquone in South Korea.
By Kristen SchottPublished: November 23, 2009 11:10 AM
Irvine-based Spectrum Pharmaceuticals is collaborating with Handok Pharmaceuticals to develop and commercialize its nonmuscle invasive bladder cancer treatment, apaziquone, in South Korea. Handok will pay Spectrum more than $19 million in upfront and potential milestone fees.
It's a positive move for Spectrum: The collaboration completes the firm's Asian partnerships for apaziquone. Spectrum is also working with Irvine-based Allergan to commercialize the drug for North America and Europe, among other markets, as well as Nippon Kayaku Co. for Asian countries except South Korea.
“This collaboration with Handok completes the company’s stated objective of achieving solid strategic partnerships that are aimed at fully exploiting developmental goals for apaziquone on a worldwide basis,” says Rajesh C. Shrotriya, M.D., chairman of the board, CEO and president of Spectrum.
NEXT PAGE >>
Related headlines
Tustin's Peregrine presents promising antiviral data
Orange County Superior Court certifies Abbott suit
Spectrum Pharmaceuticals moves forward with bladder cancer drug
|
||||
|
It's a positive move for Spectrum: The collaboration completes the firm's Asian partnerships for apaziquone. Spectrum is also working with Irvine-based Allergan to commercialize the drug for North America and Europe, among other markets, as well as Nippon Kayaku Co. for Asian countries except South Korea. “This collaboration with Handok completes the company’s stated objective of achieving solid strategic partnerships that are aimed at fully exploiting developmental goals for apaziquone on a worldwide basis,” says Rajesh C. Shrotriya, M.D., chairman of the board, CEO and president of Spectrum. NEXT PAGE >> Related headlines Tustin's Peregrine presents promising antiviral data Orange County Superior Court certifies Abbott suit Spectrum Pharmaceuticals moves forward with bladder cancer drug |
||||
